BioCentury | Apr 14, 2021

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

Immune medicines company Repertoire Immune Medicines Inc. raised $189 million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP...
BioCentury | Mar 9, 2021
Product Development

Palmoplantar pustulosis pipeline: Data Byte

AnaptysBio’s Phase II miss for palmoplantar pustulosis (PPP) may indicate that overactive IL-36 signaling is not the dominant driver of the disease. The news could be a warning for Boehringer Ingelheim GmbH, which has spesolimab (BI...
BioCentury | Feb 19, 2021
Product Development

What works, what doesn’t and what’s next for COVID-19: Data Byte

The rise of viral variants underscores the continued need to find new treatments for COVID-19, but so far, most therapeutic candidates have performed far worse in late-stage trials than vaccines. All the vaccine candidates that...
BioCentury | Jan 8, 2021

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

Carlyle leads Abbisko’s $123M series DShanghai-based oncology company Abbisko Therapeutics Co. Ltd. raised $123 million in a series D round led by the Carlyle Group. The company named Warburg Pincus, OrbiMed, Lake Bleu Capital and an...
BioCentury | Dec 4, 2020
Product Development

AZ’s opportunity to expand the severe asthma market with tezepelumab

Phase III data from AstraZeneca and Amgen’s tezepelumab suggests the mAb could substantially expand the use of biologics in severe asthma beyond the subset of patients addressed by marketed therapies....
BioCentury | Sep 24, 2020

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

Zai prices Hong Kong offering, becomes dual-listedCross-border in-licensing company Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) raised HK$5.9 billion ($776.1 million) via an offering that will land it on the Hong Kong stock exchange. The deal’s combined...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

This is the third article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
BioCentury | Aug 27, 2020
Distillery Therapeutics

IL-25 to mitigate GvHD in the GI tract after transplant

DISEASE CATEGORY: Transplant INDICATION: Graft-versus-host disease (GvHD) IL-25 could protect against gastrointestinal GvHD by reducing the loss of goblet cells, which contribute to barrier function through mucus and antimicrobial peptide production. In patients who had...
BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline

...researchers found that PTC299 also suppresses the production of inflammatory cytokines such as IL-6, IL-17A, IL-17F...
...protein DHODH - Dihydroorotate dehydrogenase IL-6 - Interleukin-6 IL-8 (CXCL8) - Interleukin-8 IL-17A - Interleukin-17A IL-17F...
...binding lectin serine peptidase 2 (MASP2) Interleukin-6 (IL-6) Interleukin-8 (IL-8) (CXCL8) C-reactive protein (CRP) Lactate dehydrogenase (LDH) Dihydroorotate dehydrogenase (DHODH) Interleukin-17A (IL-17A) Interleukin-17F (IL-17F) Vascular...
BioCentury | May 19, 2020
Emerging Company Profile

Helmed by OrbiMed’s Wang, Inmagene debuts with Phase II autoimmune program

Inmagene emerged from stealth last week with plans to expand the biologics markets in China, starting with a Phase II psoriasis program it in-licensed from Swedish biotech Affibody. The candidate, IMG-020, is expected to be...
Items per page:
1 - 10 of 416